Mutations in the isocitrate dehydrogenase genes 1 and 2 (IDH1/IDH2) define a glioma subtype associated with improved patient outcome in comparison to IDH-wildtype gliomas with molecular features of glioblastoma [16, 41]. This evidence concerns the gene IDH1 and glioblastoma.